Previous 10 | Next 10 |
2024-04-06 06:13:00 ET 3 Top Strategies to Trade Options With Penny Stocks in 2024 Trading penny stocks through options presents a dynamic avenue for investors looking to enhance their portfolios with high-potential, yet affordable securities. The intersection of options trading and p...
2024-04-05 10:56:25 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking ...
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on dis...
2024-04-02 19:00:11 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2023 Earnings Call Apr 02, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen (OCGN) Q4 2023 Earnings Call Transcript
2024-04-02 11:19:08 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen shares make gains after US court dismisses class action lawsuits Ocugen hits a 52-week high after decision to lower quorum requirement...
2024-04-02 08:37:57 ET More on Pre-market losers & stocks. Hut 8 Mining Corp. (HUT) Q4 2023 Earnings Call Transcript From Bull To Bear: Recent Events Drove Me To Exit My Position In HUT 8 Hut 8 Post-Merger Comprehensive Thesis: JCapital Research Might Be Right ...
Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (...
Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused o...
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
News, Short Squeeze, Breakout and More Instantly...
Ocugen, Inc. Company Name:
OCGN Stock Symbol:
NYSE Market:
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechn...
2024-05-29 12:53:53 ET Ocugen (NASDAQ: OCGN) stock price is doing well this year as investors focus on its ongoing drug trials and its milestones. It has soared by over 177% this year, outperforming the S&P 500, Nasdaq 100, and the iShars Biotechnology ETF (IBB), which has dropped b...
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discoverin...